Marzia Palma

Publications
CV
Public outreach and news

Articles

Journal article: 2024;1(2):100006

Frequent response monitoring in chronic lymphocytic leukemia clinical trials: what is the value?

Mattsson A; Lundin J; Mulder TA; Sylvan SE; Palma M; Hansson L; Österborg A
Journal article: BLOOD. 2023;142:5716

A CX3CR1 (fractalkine receptor) Small Molecular Antagonist (KAND567) Suppressed the Growth Promoting Effect of Monocytes on Chronic Lymphocytic Leukemia Cells

Hojjat-Farsangi M; Zhong W; Mulder T; Svensson A; Lundin J; Palma M; Schultz J; Olin T; Wahlin B; Osterborg A; Kokhaei P; Mellstedt H
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2023;111(5):748-756

Incidence of cardiovascular and bleeding events and reasons for discontinuation in patients with chronic lymphocytic leukemia treated with ibrutinib-A retrospective analysis on consecutive patients from a well-defined region.

Andersson ML; Johansson H; Österborg A; Månsson-Broberg A; Hansson L; Palma M
Journal article: HEMASPHERE. 2023;7(Suppl):e18051e0

P609: EFFECT OF LONG‐TERM ZANUBRUTINIB TREATMENT ON T‐CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: A STUDY CONDUCTED IN PARALLEL WITH THE BGB‐3111‐304 AND 305 TRIALS.

Andersson M; Mulder TA; Heimersson K; Sönnert‐Husa S; Giertz A; Hansson L; Karlsson C; Lundin J; Österborg A; Palma M
Journal article: HEMASPHERE. 2023;7(Suppl):e28011bd

PB1924: INCIDENCE OF CARDIOVASCULAR AND BLEEDING EVENTS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS (CLL) TREATED WITH IBRUTINIB – A RETROSPECTIVE ANALYSIS ON CONSECUTIVE PATIENTS FROM A WELL‐DEFINED REGION.

Andersson M; Johansson H; Österborg A; Månsson‐Broberg A; Hansson L; Palma M
Article: JOURNAL OF HEMATOLOGY. 2023;12(4):170-175

Local and Systemic Immunity During Five Vaccinations Against SARS-CoV-2 in Zanubrutinib-Treated Patients With Chronic Lymphocytic Leukemia.

Andersson M; Wu J; Wullimann D; Gao Y; Aberg M; Muschiol S; Healy K; Naud S; Bogdanovic G; Palma M; Mellstedt H; Chen P; Ljunggren H-G; Hansson L; Sallberg Chen M; Buggert M; Ingelman-Sundberg HM; Osterborg A
Journal article: HEMATOLOGICAL ONCOLOGY. 2023;41(S2):318

STING is Expressed by Hodgkin and Reed Sternberg (HRS) Cells in a Subset of Classical Hodgkin Lymphoma (cHL) and Correlates with Tumor Microenvironment and Immune Response

Xagoraris I; Mulder T; Stathopoulou K; Xyderou P; Andersson M; Palma M; Rassidakis G
Journal article: HEMATOLOGICAL ONCOLOGY. 2023;41(S2):677

TREATMENT STRATEGIES AND PROGNOSTIC FACTORS FOR THE OUTCOME OF PATIENTS WITH HODGKIN LYMPHOMA EXPERIENCING VERY LATE RELAPSES AFTER CHEMOTHERAPY ± RADIOTHERAPY

Vassilakopoulos TP; Liaskas A; Rizzuto G; Symeonidis A; Palma M; Angelopoulou MK; Giatra C; Spanoudakis E; Oikonomopoulos P; Kondopidou FN; Dimou M; Musseti A; Xagoraris I; Siakantaris M; Panitsas F; Asimakopoulos J; Arapaki M; Chatzidimitriou C; Belia M; Sachanas S; Korkolopoulou P; Cabras A; Variami E; Panayotidis P; Bakiri M; Karmiris T; Rassidakis G; Corradini P; Pangalis GA; Viviani S
Journal article: HEMATOLOGICAL ONCOLOGY. 2023;41(S2):369-370

Secondary cancer is the leading cause of death 15 years or more after diagnosis of early‐stage Hodgkin lymphoma

Lagerlöf I; Fohlin H; Enblad G; Glimelius B; Goldkuhl C; Palma M; Glimelius I; Molin D
Article: HEMASPHERE. 2022;6(11):e794

Immune Biomarkers in the Peripheral Blood and Tumor Microenvironment of Classical Hodgkin Lymphoma Patients in Relation to Tumor Burden and Response to Treatment.

Mulder TA; Andersson ML; Peña-Pérez L; Heimersson K; Xagoraris I; Wahlin BE; Månsson R; Hansson L; Rassidakis G; Palma M
Journal article: HEMASPHERE. 2022;6(Suppl):15-16

P032: Circulating immune biomarkers in classical Hodgkin lymphoma in relation to tumor burden and response to treatment.

Mulder TA; Andersson ML; Peña‐Pérez L; Heimersson K; Xagoraris I; Wahlin BE; Månsson R; Hansson L; Rassidakis GZ; Palma M
Journal article: HEMASPHERE. 2022;6(Suppl):53

P114: Very late relapses in patients with Hodgkin Lymphoma occuring ≥5 years after initial treament with chemotherapy ± radiotherapy: Treatment strategies and prognostic factors for the outcome

Vassilakopoulos TP; Liaskas A; Rizzuto G; Symeonidis A; Palma M; Angelopoulou MK; Giatra C; Kondopidou F; Dimou M; Musseti A; Xagoraris I; Siakantaris M; Verigou E; Panitsas F; Asimakopoulos J; Arapaki M; Chatzidimitriou C; Belia M; Sachanas S; Korkolopoulou P; Cabras A; Variamis E; Panayiotidis P; Bakiri M; Karmiris T; Rassidakis GZ; Corradini P; Pangalis G; Viviani S
Journal article: HEMASPHERE. 2022;6(Suppl):24

P053: The cGAS‐STING anti‐tumor immune response pathway as a potential therapeutic target in classical Hodgkin Lymphoma (cHL)

Xagoraris I; Stathopoulou K; Xyderou P; Palma M; Drakos E; Vassilakopoulos TP; Rassidakis GZ
Journal article: HEMASPHERE. 2022;6(Suppl ):42

P091: Early analysis of the PRO-Hodgkin study: Clinical investigation of pencil beam scanning proton treatment in Hodgkin lymphoma patients

Goldkuhl C; Dasu A; Bäck A; Enblad G; Glimelius I; Hall A; Hansson L; Jerlström. U; Johansson A-S; Kahlmeter-Brandell J; Linderoth J; Palma M; Rylander H; Enmark M; Molin D
Journal article: HEMASPHERE. 2022;6(Suppl):1168-1169

P1283: CIRCULATING IMMUNE CELLS IN CLASSICAL HODGKIN LYMPHOMA IN RELATION TO TUMOR BURDEN AND TREATMENT

Mulder TA; Andersson ML; Heimersson K; Xagoraris I; Wahlin BE; Rassidakis G; Hansson L; Palma M
Article: JOURNAL OF CLINICAL ONCOLOGY. 2022;40(13):1487-1496

Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy.

Lagerlöf I; Fohlin H; Enblad G; Glimelius B; Goldkuhl C; Palma M; Åkesson L; Glimelius I; Molin D
Article: LEUKEMIA. 2022;36(2):476-481

Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients.

Blixt L; Bogdanovic G; Buggert M; Gao Y; Hober S; Healy K; Johansson H; Kjellander C; Mravinacova S; Muschiol S; Nilsson P; Palma M; Pin E; Smith CIE; Stromberg O; Sällberg Chen M; Zain R; Hansson L; Österborg A
Article: EJHAEM. 2021;2(3):525-529

Temporary cessation of ibrutinib results in reduced grade 3-4 infections and durable remissions-Interim analysis of an on-off-repeat Phase 1b/2 study in patients with chronic lymphocytic leukemia.

Lundin J; Mulder TA; Kättström M; Wästerlid T; Uddevik A; Mellstedt H; Heimersson K; Hansson L; Palma M; Österborg A
Article: EJHAEM. 2021;2(3):498-502

A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of ibrutinib-resistant ROR1+ CLL cells.

Ghaderi A; Okhovat M-A; Wikanthi LSS; Svensson A; Palma M; Schultz J; Olin T; Österborg A; Mellstedt H; Hojjat-Farsangi M
Article: EJHAEM. 2021;2(3):400-412

Real-world data on treatment concepts in classical Hodgkin lymphoma in Sweden 2000-2014, focusing on patients aged >60 years.

Wahlin BE; Övergaard N; Peterson S; Digkas E; Glimelius I; Lagerlöf I; Johansson A-S; Palma M; Hansson L; Linderoth J; Goldkuhl C; Molin D
Article: HEMASPHERE. 2021;5(5):e564

Ibrutinib Has Time-dependent On- and Off-target Effects on Plasma Biomarkers and Immune Cells in Chronic Lymphocytic Leukemia.

Mulder TA; Peña-Pérez L; Berglöf A; Meinke S; Estupiñán HY; Heimersson K; Zain R; Månsson R; Smith CIE; Palma M
Journal article: HEMASPHERE. 2021;5(5)

Ibrutinib Has Time-dependent On- and Off-target Effects on Plasma Biomarkers and Immune Cells in Chronic Lymphocytic Leukemia

Mulder TA; Pena-Perez L; Berglof A; Meinke S; Estupinan HY; Heimersson K; Zain R; Mansson R; Smith CIE; Palma M
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2020;188(5):685-691

No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy.

Lagerlöf I; Holte H; Glimelius I; Björkholm M; Enblad G; Erlanson M; Fluge Ø; Fohlin H; Fosså A; Goldkuhl C; Gustavsson A; Johansson A-S; Linderoth J; Nome O; Palma M; Åkesson L; Østenstad B; Raud C; Glimelius B; Molin D
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2018;183(2):212-224

Ibrutinib induces rapid down-regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia-related genes in blood and lymph nodes.

Palma M; Krstic A; Peña Perez L; Berglöf A; Meinke S; Wang Q; Blomberg KEM; Kamali-Moghaddam M; Shen Q; Jaremko G; Lundin J; De Paepe A; Höglund P; Kimby E; Österborg A; Månsson R; Smith CIE
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2018;101(1):68-77

Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients.

Palma M; Hansson L; Mulder TA; Adamson L; Näsman-Glaser B; Eriksson I; Heimersson K; Ryblom H; Mozaffari F; Svensson A; Gentilcore G; Österborg A; Mellstedt H
Article: CLINICAL CANCER RESEARCH. 2018;24(8):1834-1844

Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML.

Björklund AT; Carlsten M; Sohlberg E; Liu LL; Clancy T; Karimi M; Cooley S; Miller JS; Klimkowska M; Schaffer M; Watz E; Wikström K; Blomberg P; Wahlin BE; Palma M; Hansson L; Ljungman P; Hellström-Lindberg E; Ljunggren H-G; Malmberg K-J
Article: PLOS ONE. 2018;13(2):e0192839

Autologous T cells expressing the oncogenic transcription factor KLF6-SV1 prevent apoptosis of chronic lymphocytic leukemia cells.

Kokhaei P; Hojjat-Farsangi M; Mozaffari F; Moshfegh A; Pak F; Rashidy-Pour A; Palma M; Hansson L; Österborg A; Mellstedt H
Article: HAEMATOLOGICA. 2017;102(3):562-572

T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers.

Palma M; Gentilcore G; Heimersson K; Mozaffari F; Näsman-Glaser B; Young E; Rosenquist R; Hansson L; Österborg A; Mellstedt H
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2017;66(1):91-102

Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints.

Winqvist M; Mozaffari F; Palma M; Eketorp Sylvan S; Hansson L; Mellstedt H; Österborg A; Lundin J
Article: EUROPEAN JOURNAL OF IMMUNOLOGY. 2015;45(6):1783-1793

Dendritic cell regulation of NK-cell responses involves lymphotoxin-α, IL-12, and TGF-β.

Sarhan D; Palma M; Mao Y; Adamson L; Kiessling R; Mellstedt H; Österborg A; Lundqvist A
Journal article: BLOOD. 2014;124(21):1120

Early and Transient Microchimerism Associated with Complete Remission after Adoptively Transferred Haploidentical NK Cells Against High Risk Myelodysplastic Syndrome and Refractory Acute Myeloid Leukemia

Bjorklund AT; Carlsten M; Schaffer M; Liu L; Cooley SA; Miller JS; Watz E; Palma M; Hansson L; Wahlin BE; Mollgard L; Hagglund H; Blomberg P; Ljungman PT; Hellstrom-Lindberg E; Ljunggren H-G; Malmberg K-J
Article: ANNALS OF HEMATOLOGY. 2014;93(10):1725-1733

Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL)-a single region experience on consecutive patients.

Eketorp Sylvan S; Lundin J; Ipek M; Palma M; Karlsson C; Hansson L
Journal article: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2014;2(Suppl 2):p18

P27. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL) – a single region experience on consecutive patients

Sylvan SE; Lundin J; Ipek M; Palma M; Karlsson C; Hansson L
Article: EXPERIMENTAL HEMATOLOGY. 2013;41(7):615-626

Telomere length and expression of human telomerase reverse transcriptase splice variants in chronic lymphocytic leukemia.

Palma M; Parker A; Hojjat-Farsangi M; Forster J; Kokhaei P; Hansson L; Osterborg A; Mellstedt H
Article: PLOS ONE. 2013;8(10):e78339

The tyrosine kinase receptor ROR1 is constitutively phosphorylated in chronic lymphocytic leukemia (CLL) cells.

Hojjat-Farsangi M; Khan AS; Daneshmanesh AH; Moshfegh A; Sandin A; Mansouri L; Palma M; Lundin J; Österborg A; Mellstedt H
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2013;62(1):51-63

T cells from indolent CLL patients prevent apoptosis of leukemic B cells in vitro and have altered gene expression profile.

Kiaii S; Kokhaei P; Mozaffari F; Rossmann E; Pak F; Moshfegh A; Palma M; Hansson L; Mashayekhi K; Hojjat-Farsangi M; Österborg A; Choudhury A; Mellstedt H
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2012;61(6):865-879

Vaccination with dendritic cells loaded with tumor apoptotic bodies (Apo-DC) in patients with chronic lymphocytic leukemia: effects of various adjuvants and definition of immune response criteria.

Palma M; Hansson L; Choudhury A; Näsman-Glaser B; Eriksson I; Adamson L; Rossmann E; Widén K; Horváth R; Kokhaei P; Vertuani S; Mellstedt H; Osterborg A
Journal article: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2011;11:s145

1.7 Telomere Length and Expression of Human Telomerase Reverse Transcriptase Splice Variants in Chronic Lymphocytic Leukemia

Palma M; Parker A; Forster J; Kokhaei P; Hansson L; Hojjat-Farsangi M; Österborg A; Mellstedt H
Journal article: BLOOD. 2010;116(21):2413

Expression of Human Telomerase Reverse Transcriptase (hTERT) Splice Variants In Chronic Lymphocytic Leukemia (CLL)

Palma M; Kokhaei P; Hansson L; Hojat-Farsangi M; Choudhury AR; Osterborg A; Mellstedt H
Article: MINERVA CHIRURGICA. 2009;64(6):643-653

Cancer vaccines for non-small-cell lung cancer.

Palma M; Choudhury A; Mellstedt H
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2009;69(6):529-536

Generation of a dendritic cell-based vaccine in chronic lymphocytic leukaemia using CliniMACS platform for large-scale production.

Adamson L; Palma M; Choudhury A; Eriksson I; Näsman-Glaser B; Hansson M; Hansson L; Kokhaei P; Osterborg A; Mellstedt H
Journal article: BLOOD. 2008;112(11):2071

T Cells from Patients with Chronic Lymphocytic Leukaemia Prevent Apoptosis of Autologous CLL Cells in a Dose- and Cell:Cell-Contact Dependent Fashion; Rationale for New Therapeutic Possibilities.

Rossmann E; Kokhaei P; Mozaffari F; Palma M; Osterborg A; Mellstedt H; Choudhury AR
Article: CLINICAL LUNG CANCER. 2008;9 Suppl 1:S37-S44

The future of cancer vaccines for non-small-cell lung cancer: ongoing trials.

Choudhury A; Palma M; Mellstedt H
Journal article: BLOOD. 2007;110(11):2061

Immunological Responses in CLL Patients Vaccinated with Autologous Dendritic Cells Loaded with Apoptotic Bodies (Apo-DC).

Choudhury A; Palma M; Hansson L; Widen K; Eriksson I; Nasman-Glaser B; Adamson L; Osterborg A; Mellstedt H
Article: EXPERIMENTAL HEMATOLOGY. 2007;35(2):297-304

Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells.

Kokhaei P; Palma M; Hansson L; Osterborg A; Mellstedt H; Choudhury A
Article: CYTOTHERAPY. 2006;8(4):318-326

Generation of DC-based vaccine for therapy of B-CLL patients. Comparison of two methods for enriching monocytic precursors.

Kokhaei P; Adamson L; Palma M; Osterborg A; Pisa P; Choudhury A; Mellstedt H
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2005;23(16_suppl):2577

Telomerase - a tumor antigen in chronic lymphocytic leukemia (CLL) induces spontaneously autologous leukemia specific cytotoxic T lymphocytes

Kokhaei P; Palma M; Hansson L; Ã-sterborg A; Choudhury A; Mellstedt H
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2004;279(29):30830-30835

Specific role for p300/CREB-binding protein-associated factor activity in E2F1 stabilization in response to DNA damage.

Ianari A; Gallo R; Palma M; Alesse E; Gulino A
Article: ANTICANCER RESEARCH. 2003;23(2C):1917-1922

Hepatic arterial continuous infusion (HACI) of oxaliplatin in patients with unresectable liver metastases from colorectal cancer.

Mancuso A; Giuliani R; Accettura C; Palma M; D'Auria G; Cecere F; Paoluzzi L; Bezzi M; Massidda B; Cortesi E
Article: TUMORI JOURNAL. 2002;88(6):527-529

Atrial fibrillation during adjuvant chemotherapy with docetaxel: a case report.

Palma M; Mancuso A; Grifalchi F; Lugini A; Pizzardi N; Cortesi E
Article: TUMORI JOURNAL. 2000;86(5):424-427

Fulminant hepatic failure caused by diffuse intrasinusoidal metastatic liver disease: a case report.

Martelli O; Coppola L; De Quarto AL; Palma M; Sarmiento R; Foggi CM
Show more

All other publications

Letter: ACTA ONCOLOGICA. 2023;62(6):560-564

The BioLymph study - implementing precision medicine approaches in lymphoma diagnostics, treatment and follow-up: feasibility and first results.

Smedby KE; Wästerlid T; Tham E; Haider Z; Joelsson J; Thorvaldsdottir B; Krstic A; Wahlin BE; Foroughi-Asl H; Karlsson C; Eloranta S; Saft L; Palma M; Kwiecinska A; Hansson L; Österborg A; Wirta V; Rassidakis G; Sander B; Sonnevi K; Rosenquist R
Meeting abstract: BLOOD. 2022;140:3579-3580

Modulation of the CGAS-Sting Anti-Tumor Immune Response Pathway in an NF-KB-Dependent or -Independent Manner As a Potential Therapeutic Target in Classical Hodgkin Lymphoma (cHL)

Xagoraris I; Stathopoulou K; Xyderou P; Palma M; Drakos E; Vassilakopoulos TP; Rassidakis GZ
Review: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2022;95(4):e13153

Do reduced numbers of plasmacytoid dendritic cells contribute to the aggressive clinical course of COVID-19 in chronic lymphocytic leukaemia?

Smith CIE; Zain R; Österborg A; Palma M; Buggert M; Bergman P; Bryceson Y
Review: FRONTIERS IN IMMUNOLOGY. 2021;12:686768

BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects.

Palma M; Mulder TA; Österborg A
Conference publication: LEUKEMIA & LYMPHOMA. 2020;61:81-84

Effect of long-term ibrutinib treatment on T-cell number and profile in relapsed or refractory chronic lymphocytic leukemia patients: correlation with clinical response and tumor burden up to 4-years follow-up

Palma M; Heimersson K; Mulder T; Mellstedt H; Osterborg A
Conference publication: BLOOD. 2019;134:5445

Expression of the Fractalkine Receptor (CX3CR1) Is Significantly Increased in Immune Cells of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma patients with Active Disease

Palma M; Mulder TA; Heimersson K; Rathje L-S; Olin T; Schultz J; Mellstedt H; Osterborg A
Review: CANCERS. 2019;11(7):E915-915

Targeting the Immune Microenvironment in Lymphomas of B-Cell Origin: From Biology to Clinical Application.

Mulder TA; Wahlin BE; Österborg A; Palma M
Meeting abstract: BLOOD. 2018;132:4421

Reduction of Tumor Burden Rather Than Off-Target Effects Drives Changes in T-Cell Number and Profile during Prolonged Ibrutinib Treatement in Relapsed or Refactory Chronic Lymphocytic Leukemia Patients

Palma M; Heimersson K; Mulder TA; Nasman-Glaser B; Osterborg A; Mellstedt H
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2018;182(4):590-594

Dual targeting of Bruton tyrosine kinase and CD52 induces minimal residual disease-negativity in the bone marrow of poor-prognosis chronic lymphocytic leukaemia patients but is associated with opportunistic infections - Results from a phase I study.

Winqvist M; Palma M; Heimersson K; Mellstedt H; Österborg A; Lundin J
Conference publication: BLOOD. 2017;130

Complete Remission and Signs of Immunoediting Following Haploidentical NK Cell Therapy in Refractory High-Risk MDS and AML Ell Therapy in Refractory High-Risk MDS and AML

Bjorklund AT; Carlsten M; Sohlberg E; Clancy T; Liu L; Karimi M; Cooley S; Miller JS; Watz E; Wahlin BE; Palma M; Hansson L; Ljungman P; Hellstrom-Lindberg E; Ljunggren H-G; Malmberg K-J
Conference publication: LEUKEMIA & LYMPHOMA. 2017;58:38-39

Vaccination with dendritic cells loaded with autologous leukemic cells in combination with low-dose lenalidomide in chronic lymphocytic leukemia (CLL) patients: an early clinical trial

Heimersson K; Mozaffari F; Mulder T; Palma M; Hansson L; Adamson L; Nasman-Glaser B; Svensson A; Gentilcore G; Osterborg A; Mellstedt H
Meeting abstract: BLOOD. 2016;128(22):3235

Very Early Effects of Ibrutinib on Tumor and Immune Cells in Blood and Lymph Nodes in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Patients

Palma M; Krstic A; Berglof A; Wang Q; Blomberg E; Meinke S; Kamali-Moghaddam M; Shen Q; Jaremko G; Lundin J; Kimby E; Hoglund P; Mansson R; Osterborg A; Smith E
Conference publication: HAEMATOLOGICA. 2016;101:22

HODGKIN LYMPHOMA IN SWEDEN SINCE 2000: BETTER SURVIVAL ONLY IN ELDERLY WOMEN - A SWEDISH LYMPHOMA REGISTRY STUDY

Wahlin BE; Overgaard N; Peterson S; Digkas E; Glimelius I; Lagerlof I; Johansson A-S; Palma M; Hansson L; Linderoth J; Goldkuhl C; Molin D
Conference publication: EUROPEAN JOURNAL OF CANCER. 2016;55:S7

Expression of immune checkpoint molecules and activation markers in T cells from chronic lymphocytic leukemia (CL) patients

Palma M; Gentilcore G; Mozaffari F; Heimersson K; Nasman-Glaser B; Hansson L; Osterborg A; Mellstedt H
Conference publication: HAEMATOLOGICA. 2016;101:9

PHENOTYPIC CHARACTERIZATION OF CIRCULATING LYMPHOCYTES IN HODGKIN'S LYMPHOMA WITH FOCUS ON T CELLS

Palma M; Heimersson K; Nasman-Glaser B; Hansson L
Conference publication: BLOOD. 2015;126(23):4164

In Vivo Effects of Lenalidomide on T Cell Proliferation and Immune Checkpoint Molecules in Patients with Advanced Stage CLL: Results from a Phase II Study

Winqvist M; Mozaffari F; Palma M; Sylvan SE; Mellstedt H; Osterborg A; Lundin J
Conference publication: BLOOD. 2015;126(23):4132

T Cells from Chronic Lymphocytic Leukemia (CLL) Patients Display Dysregulated Expression of Immune Checkpoint Molecules and Activation Markers Mainly Restricted to CD4⁺ Cells and Correlated with Disease Activity

Palma M; Gentilcore G; Mozaffari F; Heimersson K; Nasman-Glaser B; Hansson L; Osterborg A; Mellstedt H
Review: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2015;82(3):208-217

Targets for Ibrutinib Beyond B Cell Malignancies.

Berglöf A; Hamasy A; Meinke S; Palma M; Krstic A; Månsson R; Kimby E; Österborg A; Smith CIE
Meeting abstract: LEUKEMIA RESEARCH. 2015;39:S25-S26

ADOPTIVELY TRANSFERRED HAPLOIDENTICAL NK CELLS AGAINST REFRACTORY MDS, HIGH-RISK MDS AND REFRACTORY AML AS A BRIDGE TO TRANSPLANTATION. COMPLETE REMISSION ASSOCIATED WITH DETECTABLE NK CELLS

Bjorklund AT; Carlsten M; Liu L; Schaffer M; Watz E; Palma M; Hansson L; Mollgard L; Cooley SA; Miller JS; Ljungman PT; Hellstrom-Lindberg E; Ljunggren HG; Malmberg KJ
Conference publication: BLOOD. 2014;124(21):4685

Vaccination with Dendritic Cells Loaded with Autologous Leukemic Cells in Combination with Low-Dose Lenalidomide Induced Immune Responses in Chronic Lymphocytic Leukemia (CLL) Patients

Hansson L; Palma M; Adamson L; Ryblom H; Nasman-Glaser B; Eriksson I; Heimersson K; Gentilcore G; Mellstedt H; Osterborg A
Conference publication: BLOOD. 2014;124(21):4140

Regulation of Natural Killer Cell Responses By Dendritic Cells Via Lymphotoxin-Alpha, Interleukin-12, and Tumor Growth Factor-Beta

Sarhan D; Palma M; Mao Y; Adamson L; Kiessling R; Mellstedt H; Osterborg A; Lundqvist A
Conference publication: BONE MARROW TRANSPLANTATION. 2014;49:S134-S135

INTERIM REPORT OF A CLINICAL STUDY WITH HAPLOIDENTICAL NK-CELLS AGAINST HIGH RISK MDS AND AML

Bjorklund AT; Carlsten M; Liu L; Er MS; Cooley S; Miller JS; Watz E; Wahlin B; Palma M; Hansson L; Ljungman P; Hellstrom-Lindberg E; Ljunggren H-G; Malmberg K-J
Conference publication: HAEMATOLOGICA. 2010;95:476

VACCINATION WITH DENDRITIC CELLS LOADED WITH APOPTOTIC BODIES (APO-DC) OF AUTOLOGOUS LEUKEMIC CELLS INDUCES IMMUNOLOGIC RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS

Hansson L; Palma M; Adamson L; Eriksson I; Nasman-Glaser B; Kokhaei P; Widen K; Choudhury A; Osterborg A; Mellstedt H
Conference publication: BLOOD. 2010;116(21):1001

Expression of Human Telomerase Reverse Transcriptase (hTERT) Splice Variants In Chronic Lymphocytic Leukemia (CLL)

Palma M; Kokhaei P; Hansson L; Hojat-Farsangi M; Choudhury AR; Osterborg A; Mellstedt H
Published conference paper: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2008;57(11):1705-1710

Development of a dendritic cell-based vaccine for chronic lymphocytic leukemia.

Palma M; Adamson L; Hansson L; Kokhaei P; Rezvany R; Mellstedt H; Osterborg A; Choudhury A
Conference publication: ANNALS OF ONCOLOGY. 2008;19:164

VACCINATION OF CLL PATIENTS WITH AUTOLOGOUS DENDRITIC CELLS LOADED WITH APOPTOTIC BODIES (APO-DC): A PHASE I-II CLINICAL TRIAL

Palma M; Hansson L; Adamson L; Eriksson I; Nasman-Glaser B; Widen K; Choudhury AR; Osterborg A; Mellstedt H
Conference publication: BLOOD. 2008;112(11):721

T Cells from Patients with Chronic Lymphocytic Leukaemia Prevent Apoptosis of Autologous CLL Cells in a Dose- and Cell:Cell-Contact Dependent Fashion; Rationale for New Therapeutic Possibilities

Rossmann E; Kokhaei P; Mozaffari F; Palma M; Osterborg A; Mellstedt H; Choudhury AR
Conference publication: ANNALS OF ONCOLOGY. 2008;19:234-235

T CELLS FROM CHRONIC LYMPHOCYTIC LEUKAEMIA PATIENTS SUPPORT TUMOR CELL SURVIVAL IN VITRO

Kokhaei P; Mozaffari F; Palma M; Rosmann E; Osterborg A; Mellstedt H
Conference publication: BLOOD. 2007;110(11):614A

Immunological responses in CLL patients vaccinated with autologous dendritic cells loaded with apoptotic bodies (Apo-DC)

Choudhury A; Palma M; Hansson L; Widen K; Eriksson I; Nasman-Glaser B; Adamson L; Osterborg A; Mellstedt H
Published conference paper: ANNALS OF ONCOLOGY. 2006;17 Suppl 10:X144-X154

The biology and treatment of chronic lymphocytic leukemia.

Palma M; Kokhaei P; Lundin J; Choudhury A; Mellstedt H; Osterborg A
Review: MECHANISMS AND THERAPY OF LIVER CANCER. 2006;95:147-202

Clinical results of vaccine therapy for cancer: learning from history for improving the future.

Choudhury A; Mosolits S; Kokhaei P; Hansson L; Palma M; Mellstedt H
Review: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2006;57(1):1-23

BRCA1 and BRCA2: the genetic testing and the current management options for mutation carriers.

Palma M; Ristori E; Ricevuto E; Giannini G; Gulino A
Conference publication: ANNALS OF ONCOLOGY. 2006;17:207

Vaccination of B-CLL patients with autologous dendritic cells loaded with leukemia-derived apoptotic bodies

Choudhury A; Hansson L; Palma M; Kokhaei P; Adamson L; Osterborg A; Mellstedt H
Conference publication: ANNALS OF ONCOLOGY. 2006;17:60-61

HTERT (human telomerase reverse transcriptase) Σ-insert splice variant (INS1) expression in B-chronic lymphocytic leukemia (B-CLL)

Palma M; Kokhaei P; Kiaii S; Nasman-Glaser B; Hansson L; Osterborg A; Choudhury A; Mellstedt H
Published conference paper: ANNALS OF ONCOLOGY. 2005;16 Suppl 2:ii113-ii123

Biology and treatment of chronic lymphocytic leukemia.

Kokhaei P; Palma M; Mellstedt H; Choudhury A
Conference publication: EXPERIMENTAL HEMATOLOGY. 2005;33(7):97

A telomerase-derived peptide antigen generates antileukemic T cells from B-CLL patients in vitro

Choudhury A; Palma M; Kokhaei P; Hanson L; Osterborg A; Mellstedt H
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2005;23(16):185S

Telomerase - a tumor antigen in chronic lymphocytic leukemia (CLL) induces spontaneously autologous leukemia specific cytotoxic T lymphocytes.

Kokhaei P; Palma M; Hansson L; A-sterborg A; Choudhury A; Mellstedt H
Show more

Employments

Affiliated to Research, Department of Oncology-Pathology, Karolinska Institutet, 2023-2026

Degrees and Education

Docent, Oncology, Oncology-pathology, Karolinska Institute, 2023
Degree Of Doctor Of Philosophy, Department of Oncology-Pathology, Karolinska Institutet, 2010

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI